MYO18B and ovarian serous adenocarcinoma: For example, high FZD10, MKX, FAM83A and MYO18B methylation were related with response to platinum-based chemotherapy in advanced stage high-grade serous ovarian cancer (HGSOC), and these markers might be used to predict platinum sensitivity in HGSOC patients (Tomar et al., 2017).